MedTrace Logo

The Effect of Vasopressors on the Anti Xa Response to Enoxaparin in Critically Ill Patients

NCT00351663 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 39

Last updated 2016-04-20

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy of 3 different dosing regimens of enoxaparin in achieving adequate antithrombotic aFXa levels in critically ill patients.

The relationship between appearance of DVT and antithrombotic aFXa levels will also be assessed and risk factors associated with inadequate aFXa levels under standard enoxaparin dosages will be searched for.

Conditions

  • Venous Thrombosis
  • Critical Illness

Interventions

DRUG

Enoxaparine

Patients considered eligible will be divided into 2 groups- those receiving vasopressor support and those not receiving vasopressor support at the time of inclusion. The patients in each group will be randomized to receive enoxaparin in accordance with one of the following DVT prophylaxis protocols: 1. Intravenous Enoxaparine according to their weight (0.5mg/kg x 1/day) 2. Subcutaneous Enoxaparine according to their weight (0.5mg/kg x 1/day) 3. Subcutaneous Enoxaparine 40mg x1/day

Sponsors & Collaborators

  • Shaare Zedek Medical Center

    lead OTHER

Principal Investigators

  • Sharon Einav-Bromiker, MD · Shaare Zedek Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-02-28
Primary Completion
2014-04-30
Completion
2015-09-30

Countries

  • Israel

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00351663 on ClinicalTrials.gov